Date: 2016-04-19
Type of information: Licensing agreement
Compound: C-LiNK (CTAT)
Company: ProBioGen (Germany) Eucodis Bioscience (Austria)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism: antibody drug conjugate technology/ADC technology. C-LiNK (CTAT) is a conjugation system which covalently links, by a specific 1 step enzymatic reaction, toxins, drugs, or other substances to the C terminus of an antibody or a recombinant protein. The C-LiNK enzyme targets a short recognition sequence of 3-4 amino acids fused to the C-terminus of the to-be-conjugated protein. It then cleaves this specific sequence and covalently links the drug molecule to the antibody by a transamidation reaction. This directed conjugation approach is not interfering with the antibody’s antigen binding site, does not alter its integrity, or its manufacturability. The technology allows adjusting a defined drug-antibody ratio (DAR) and, by modifying the linker, attaching more than one drug per site, or inserting a specific cleavage site, if needed.
C-LiNK for ADC creation is available as separate, royalty-free license through ProBioGen or in combination with cell line development and manufacturing packages.
Disease:
Details: * On April 19, 2016, ProBioGen, a specialist for contract development and manufacturing of complex glycoproteins and Eucodis Bioscience, an expert in enzyme engineering, jointly announced the signature of an exclusive license agreement on C-LiNK (CTAT), an innovative, site-specific ADC conjugation technology. Under the agreement ProBioGen gains exclusive rights to commercialize Eucodis’ enzymatic C-terminal linking technology, and to offer it, together with its antibody development services, royalty-free to ADC-developing parties.
Financial terms:
Latest news:
